JY
BDRX

Jeff Yass’s Biodexa Pharmaceuticals BDRX Stock Holding History

Jeff Yass’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24
Closed -$27K – 11975
2024
Q2 		$27K Buy
+24
New +$31.4K ﹤0.01% 11591
2023
Q4 		– Sell
-9
Closed -$57.2K – 12339
2023
Q3 		$57.2K Buy
+9
New +$62K ﹤0.01% 11237
2022
Q3 		– Hold
0
– -$8K – 13155
2022
Q2 		– Hold
0
– – – 12548
2021
Q4 		– Hold
0
– -$28K – 13104
2021
Q3 		– Hold
0
– – – 12496
2021
Q2 		– Hold
0
– – – 12414
2021
Q1 		– Hold
0
– -$159K – 12230
2020
Q4 		– Hold
0
– – – 10216
2020
Q3 		– Hold
0
– – – 10130
2019
Q4 		– Hold
0
– -$23K – 9709
2019
Q3 		– Hold
0
– – – 9929
2019
Q2 		– Hold
0
– -$11K – 10206
2019
Q1 		– Hold
0
– – – 8650
2018
Q4 		– Hold
0
– – – 8711
2018
Q3 		– Hold
0
– -$12K – 9205
2018
Q2 		– Hold
0
– – – 9458
2018
Q1 		– Hold
0
– – – 9040

Other funds holding BDRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Jeff Yass's BDRX Position: Q3 2024 in Review

Jeff Yass sold out of Biodexa Pharmaceuticals (BDRX) in Q3 2024, closing a stake of 24 shares — an estimated $27K sold.

Jeff Yass first reported a position in BDRX in Q3 2023 and held it in 2 quarters. The position peaked at $57.2K in Q3 2023. 5 funds tracked by Wall St. Rank hold BDRX as of Q3 2024.

  • Jeff Yass reported no remaining Biodexa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Jeff Yass sold 24 Biodexa Pharmaceuticals shares in Q3 2024, an estimated $27K.
  • Jeff Yass first reported a position in Biodexa Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Jeff Yass's Biodexa Pharmaceuticals position peaked at $57.2K in Q3 2023.
  • 5 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.